FierceBiotech3 小时
GI-focused CRO Alimentiv ups trial tech with PhaseV’s adaptive machine learning software
Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology ...
FierceBiotech3 小时
Baxter CEO José Almeida to retire, effective immediately
Baxter President and CEO José Almeida has announced his retirement, effective immediately, after nearly a decade of leading ...
FierceBiotech5 小时
Sionna eyes up $156M IPO to fund cystic fibrosis trials
Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...
FierceBiotech6 小时
Sanofi-backed AdvanCell secures $112M series C to fund targeted alpha radiopharma trial
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
FierceBiotech6 小时
Irish biotech's inhaled drug reduces depression in phase 2 trial
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
FierceBiotech9 小时
Affibody regains autoimmune asset, claims ex-partner Acelyrin unable 'to fully capitalize ...
Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, complet | Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former ...